BIONEWS
Three warning letters from the FDA's biologics office (CBER) show the agency is still naming specific clinics and setting deadlines, eighteen months after RFK Jr. disclosed receiving unproven stem cell treatments in the Caribbean.
Three CBER warning letters, dated August 14, 2026, February 11, 2026, and January 17, 2025, show the FDA's narrowest enforcement tool against unproven stem cell clinics is still active eighteen months into an administration that was expected to let the industry off the hook. The tool is the inspection-to-letter pipeline, and the letters themselves are the proof that it is still running.
The most recent letter, to R3 Medical Companies and two affiliated firms in Scottsdale, Arizona, faulted a contract manufacturer for ReBellaWJ, ReBellaXO, and ReBellaXOL, allogeneic products (cells from a donor, not the patient) derived from umbilical cord tissue. CBER issued the letter following a November 17 through December 16, 2025 inspection. The cited violations were significant deviations from current good manufacturing practice, the federal quality rules that govern how biologics are made and tested. The standard response clock is 15 working days, during which a firm is expected to lay out its corrective-action plan in writing.
The warning letter is the agency's least confrontational public enforcement tool. It carries no fine, it does not pull a license, and it does not shut a clinic door. It sets a clock and a paper trail. That clock is the active ingredient in the pipeline: an FDA inspection, a Form 483 listing observed deviations, the 15-day response window, the warning letter, and, if the company keeps selling unapproved product, a referral to the FDA's Office of Regulatory Affairs for injunction, seizure, or criminal prosecution. The first three steps are visible. The last three, for the three letters under discussion, are not in the public record, and the absence of an injunction, seizure, or prosecution means the pipeline, so far, has only run as far as its slowest stage.
The February 11, 2026 letter to Dynamic Stem Cell Therapy, a Henderson, Nevada clinic run by Dr. Dale Carrison, went out over a different lane: misbranding. The clinic was marketing an umbilical-cord-derived allogeneic product on stemcellpowernow.com for indications the FDA's 2017 regenerative-medicine guidance framework does not recognize as exempt. That framework, finalized in 2017 and updated in 2019, gives the agency discretion to crack down on products that are more than minimally manipulated or used in ways outside their original function. The January 17, 2025 letter to BioStem Life Sciences, cited the manufacture of OROPRO, PROVISCUS, NEOFYL, and an amniotic product called RHEO after a September 2023 inspection. The BioStem letter predates the current administration; it is the historical baseline. The two 2026 letters are the answer to whether the pipeline survives the political change.
In June 2025, Health and Human Services Secretary Robert F. Kennedy Jr. disclosed on a podcast that he had received unproven stem cell treatments in the Caribbean for a throat condition. That disclosure, covered in a STAT+ opinion column headlined "A surprising bright spot at the FDA," suggested the agency's posture would soften. The two 2026 letters say it has not softened, at least not yet. A "surprising bright spot" is a time-limited phrase, and the column that used it stops well short of declaring a win.
The size of the in-scope market is the other half of the limit. A paper "a few years ago," as the same STAT+ column notes, counted more than 2,000 firms marketing unproven stem cell products in the United States. Even if the warning-letter pipeline is running, three letters, two of them to contract manufacturers rather than to clinics, do not move that number. The pipeline is the slowest regulatory tool that still counts as public action, and it is built for case-by-case enforcement, not industry-wide cleanup.
What would falsify the "still running" claim? Three things, each observable. A CBER guidance document withdrawing or narrowing the 2017 regenerative-medicine framework. A published staffing cut at the Office of Regulatory Affairs that empties the inspection side of the pipeline. Or a leadership decision, by the HHS Secretary or the FDA Commissioner, to pause new CBER warning letters to stem cell firms. None of those has happened. The FDA's public warning-letter feed is the place to check whether any of them do.